Eurofarma announces joint venture with SK Biopharmaceuticals for digital health solutions with AI

São Paulo, Brazil, October 21, 2025 – In a strategic move that reinforces its commitment to innovation and digital health, Eurofarma, a multinational with 100% Brazilian capital and presence in 24 countries, announces the launch of a joint venture with Korean company SK Biopharmaceuticals. The focus of the new partnership is the development and commercialization of artificial intelligence solutions for the detection and prediction of epileptic seizures, as well as the creation of a digital health ecosystem. 
 
The new company, named Mentis Care, was launched on October 20 in Toronto (Canada) and will be headquartered at the MaRS Discovery District, one of North America’s largest innovation hubs, which hosts research institutions, startups, and investors in life sciences and health. 
 
According to a MarketsandMarkets report, the global digital health market, estimated at US$180 billion in 2023, is expected to reach US$550 billion by 2028, with North America driving the largest share of this growth. 
 
“For Eurofarma, the JV represents the future we envision for healthcare, combining digital technologies and medicines for a transformative and positive leap in patients’ lives. We are a reference in central nervous system treatments in Latin America, with a broad portfolio of medicines and close relationships with psychiatrists and neurologists. For some years now, we have added digital innovation investments to our R&D activities, and since 2022, we have maintained a small operation in North America. With this new partnership, we will strengthen these fronts in a single move,” says Rodrigo Pereira, Global Executive Director of Entrepreneurship and Digital at Eurofarma. 
 
“SK Biopharmaceuticals is expanding beyond pharmaceuticals into digital healthcare to open new possibilities in patient care,” said Donghoon Lee, CEO of SK Biopharmaceuticals. “Through Mentis Care, we will advance toward patient-centered innovation by integrating AI and clinical data to improve epilepsy treatment.” 
 
“Mentis Care is an AI-driven digital health company with a mission is to help patients with epilepsy live safer and more independently through AI-powered seizure prediction and monitoring,” said Hassan Kotob, CEO of Mentis Care. “By combining the innovation capabilities of our partners, SK Biopharmaceuticals and Eurofarma, we aim to establish a new standard in digital epilepsy management for patients worldwide.” 
 
 
Strategic importance in the field of digital health 
 
Digital health is already a reality in patient care systems, especially for neurological and chronic diseases. Technologies that combine continuous monitoring, real-time data processing, and predictive AI models have the potential to anticipate seizures, alert patients and medical teams, and enable interventions before advanced symptoms appear. 
 
In epilepsy, for example, a solution capable of predicting seizures from real-time EEG data can transform treatment by reducing emergencies, improving patients’ quality of life, and providing economic benefits for health systems and insurers. 
 
Mentis Care aims to build platforms that will initially focus on the detection and prediction of epileptic seizures, but in the medium term may expand to monitoring biomarkers of other neuropsychiatric disorders, integrating patients, doctors, and partners into a digital ecosystem. 
 
The cooperation arose from an evolving relationship between the companies that began in 2022, when SK Biopharmaceuticals licensed the innovative Cenobamate (brand in the US: XCOPRI®) to Eurofarma for the promotion and commercialization of the anticonvulsant in Latin America. The product will soon be available in these countries. 
 
By positioning itself at the forefront of digital health with AI, Eurofarma maintains its purpose of combining innovation and access to generate social impact. The company sees this project as an opportunity to: 

• Remain at the forefront of technological development in health in Latin America; 
• Develop its own competencies in digital health, artificial intelligence, and continuous monitoring; 
• Establish regional leadership with innovation applied to neurology and other medical areas. 
   

About Eurofarma 
 
Founded in 1972, Eurofarma operates in the healthcare sector through the production and commercialization of products and services aimed at improving people’s quality of life. With a focus on generating shared value, the company covers key pharmaceutical segments such as prescription drugs, generics, hospital, oncology, OTC, personal care, and animal health, in addition to providing contract manufacturing services. With broad coverage across therapeutic classes, its portfolio includes over 4,000 SKUs, serving nearly all medical specialties. Eurofarma is the leader in medical prescriptions in Brazil, where it also holds second place in the generics market. The company is present in 24 countries, with full coverage across Latin America and retail leadership in the region. It also maintains operations in the United States and Africa, with more than 13,500 employees and 11 manufacturing facilities. In 2024, Eurofarma produced 600 million units. That same year, the company invested over R$ 800 million in innovation projects and achieved net revenue exceeding R$ 11 billion. 
 
 
About SK Life Science, Inc. and SK Biopharmaceuticals Co., Ltd. 
 
SK Life Science, Inc., with headquarters in Paramus, New Jersey, is a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., a pioneering South Korean company in drug development and commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with eight compounds currently in development. Utilizing target-based drug discovery, high-throughput organic screening/high content screening, computer-aided drug design, and combinatorial chemistry, the companies drive R&D efforts in biology/discovery, medicinal chemistry, pharmacology, and clinical development.

For more information:
SK Life Science visit www.SKLifeScienceInc.com. 
 
SK Biopharmaceuticals Co., Ltd. is part of SK Group, South Korea’s second-largest conglomerate. SK Group is a collection of global industry-leading companies driving innovations in energy, advanced materials, biopharmaceuticals and digital business. Based in Seoul, SK invests in building sustainable businesses around the world with a shared commitment to reducing global greenhouse gas emissions. SK companies combined have $151 billion in global annual revenue and employ more than 100,000 people worldwide.

SK Group is one of TIME's 100 Most Influential Companies of 2023. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses.

For more information about:
SK Inc., visit https://sk-inc.com/en/main/mainpage.aspx.
SK Biopharmaceuticals, visit www.skbp.com/eng.  
 
 
About Mentis Care, Inc. 
 
Mentis Care is an AI-driven health company transforming neurological care through the first predictive AI platform for brain health. The platform is designed to detect and forecast seizures and other neurological events in real time. By combining advanced machine learning with clinical expertise, Mentis Care aims to give patients and families greater safety, confidence, and peace of mind, while setting a new global standard in brain health and digital neuromonitoring.